


Diagnosis and Management of Rheumatoid Arthritis

J. ADAM RINDFLEISCH, M.D., and DANIEL MULLER, M.D., PH.D.
University of Wisconsin–Madison, Madison, Wisconsin

Rheumatoid arthritis is a chronic inflammatory disease characterized by uncontrolled proliferation of synovial tissue and a wide array of multisystem comorbidities. Prevalence is estimated to be 0.8 percent worldwide, with women twice as likely to develop the disease as men. Untreated, 20 to 30 percent of persons with rheumatoid arthritis become permanently work-disabled within two to three years of diagnosis. Genetic and environmental factors play a role in pathogenesis. Although laboratory testing and imaging studies can help confirm the diagnosis and track disease progress, rheumatoid arthritis primarily is a clinical diagnosis and no single laboratory test is diagnostic. Complications of rheumatoid arthritis may begin to develop within months of presentation; therefore, early referral to or consultation with a rheumatologist for initiation of treatment with disease-modifying antirheumatic drugs is recommended. Several promising new disease-modifying drugs recently have become available, including leflunomide, tumor necrosis factor inhibitors, and anakinra. Nonsteroidal anti-inflammatory drugs, corticosteroids, and nonpharmacologic modalities also are useful. Patients who do not respond well to a single disease-modifying drug may be candidates for combination therapy. Rheumatoid arthritis is a lifelong disease, although patients can go into remission. Physicians must be aware of common comorbidities. Progression of rheumatoid arthritis is monitored according to American College of Rheumatology criteria based on changes in specific symptoms and laboratory findings. Predictors of poor outcomes in early stages of rheumatoid arthritis include low functional score early in the disease, lower socioeconomic status, early involvement of many joints, high erythrocyte sedimentation rate or C-reactive protein level at disease onset, positive rheumatoid factor, and early radiologic changes. (*Am Fam Physician* 2005;72:1037-47, 1049-50. Copyright © 2005 American Academy of Family Physicians.)



► **Patient information:** A handout on rheumatoid arthritis, written by the authors of this article, is provided on page 1049.

Rheumatoid arthritis is characterized by persistent joint synovial tissue inflammation. Over time, bone erosion, destruction of cartilage, and complete loss of joint integrity can occur. Eventually, multiple organ systems may be affected.

Rheumatoid arthritis is the most common inflammatory arthritis, affecting 0.8 percent of the adult population worldwide. Onset usually occurs between 30 and 50 years of age. Incidence in the United States is estimated as 25 per 100,000 persons for men and 54 per 100,000 persons for women.¹ Rheumatoid arthritis is responsible for an estimated 250,000 hospitalizations and 9 million physician visits each year.² Its economic impact is magnified by the high level of func-

tional impairment it causes: untreated, 20 to 30 percent of persons with rheumatoid arthritis become permanently work-disabled within three years of diagnosis.³

Etiology and Pathophysiology

The etiology of rheumatoid arthritis is not fully understood. Evidence points to a complex interplay between environmental and genetic factors. In monozygotic twins, there is a more than 30 percent concordance rate for rheumatoid arthritis development, and 80 percent of whites with rheumatoid arthritis express the HLA-DR1 or -DR4 subtypes. These and other regions of the Major Histocompatibility Complex may confer susceptibility to more severe disease by causing a specific arthrogenic peptide to be presented to CD4⁺ T cells.⁴

SORT: KEY RECOMMENDATIONS FOR PRACTICE

<i>Clinical recommendation</i>	<i>Evidence rating</i>	<i>References</i>
Patients with rheumatoid arthritis should be treated as early as possible with DMARDs to control symptoms and delay disease progression.	A	2, 14, 15
Patients with persistent inflammatory joint disease (longer than six to eight weeks) already receiving analgesics or NSAIDs should be considered for rheumatology referral, preferably within 12 weeks.	C	13, 14
Patient education, preferably one-to-one, should be provided when rheumatoid arthritis is diagnosed.	C	29
NSAIDs should be prescribed in the lowest dose that provides symptom relief and should be cut back after a good response to DMARDs is achieved.	A	13
Gastroprotection should be used if patients are older than 65 years or have a history of peptic ulcer disease.	B	13
Intra-articular corticosteroid injections can be helpful but should not be administered more than three times in one year.	C	13
Low-dose oral corticosteroids are effective for symptom relief but have a high risk of toxicity; therefore, the lowest dosage possible should be used for the shortest period possible.	A	2
Combination therapy may be more effective than treatment with one drug alone.	A	2, 16-18
Efficacy of treatment should be monitored; changes in hemoglobin, erythrocyte sedimentation rate, and C-reactive protein may indicate treatment response, and measurement instruments such as the European League Against Rheumatism response criteria are useful for tracking disease progression.	C	2, 35
A multidisciplinary team approach is beneficial, at least in the short term; therefore, patients should have access to a wide range of health care professionals, including their primary care physicians, rheumatologists, nursing specialists, physical therapists, occupational therapists, dietitians, podiatrists, pharmacists, and social workers.	C	30
Exercise is beneficial for aerobic capacity and muscle strength with no detrimental effects on disease activity or pain levels.	C	28

DMARD = disease-modifying antirheumatic drug; NSAID = nonsteroidal anti-inflammatory drug.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 983 or <http://www.aafp.org/afpsort.xml>.

Joint damage in rheumatoid arthritis begins with the proliferation of synovial macrophages and fibroblasts after a triggering incident, possibly autoimmune or infectious. Lymphocytes infiltrate perivascular regions, and endothelial cells proliferate. Neovascularization then occurs. Blood vessels in the affected joint become occluded with small clots or inflammatory cells. Over time, inflamed synovial tissue begins to grow irregularly, forming invasive pannus tissue. Pannus invades and destroys cartilage and bone. Multiple cytokines, interleukins, proteinases, and growth factors are released, causing further joint destruction and the development of systemic complications.^{1,4}

RISK FACTORS

Female sex, a positive family history, older age, silicate exposure, and smoking are associated with an increased risk for developing rheumatoid arthritis.^{1,5,6} Consumption of more than three cups of coffee daily—particularly decaffeinated coffee—also may contribute.⁷ High vitamin D intake,⁸ tea consumption,⁷ and oral contraceptive use⁶ are associated with decreased risk. Three in four women with rheumatoid arthritis experience significant improvement in symptoms when pregnant,

usually with a recurrence after delivery.⁵ A systematic review⁹ of 24 studies did not support a link between breast implants and connective tissue disorders.

Diagnosis

TYPICAL PRESENTATION

Rheumatoid arthritis primarily is a clinical diagnosis. Patients commonly present with pain and stiffness in multiple joints, although one third of patients initially experience symptoms at just one location or a few scattered sites. In most patients, symptoms emerge over weeks to months, starting with one joint and often accompanied by prodromal symptoms of anorexia, weakness, or fatigue. In approximately 15 percent of patients, onset occurs more rapidly over days to weeks. In 8 to 15 percent of patients, symptoms begin within a few days of a specific inciting event, such as an infectious illness.⁵

Joints most commonly affected are those with the highest ratio of synovium to articular cartilage. The wrists are nearly always involved, as are the proximal interphalangeal and metacarpophalangeal joints. The distal interphalangeal joints and sacroiliac joints tend not to be affected.⁵ Rheumatoid joints typically are boggy, tender to the touch, and warm, but they usually are not

TABLE 1

Revised American Rheumatism Association Criteria for Classification of Rheumatoid Arthritis

Sign or symptom	Definition	LR+	LR-	Percentage with rheumatoid arthritis if sign or symptom is*:	
				Present	Absent
Morning stiffness	Stiffness in or around the affected joints for at least one hour after initiating movement	1.9	0.5	39	14
Arthritis of three or more joint areas	Three or more of the following joints noted to be fluid-filled or have soft tissue swelling: wrist, PIP, MCP, elbow, knee, ankle, MTP	1.4	0.5	32	13
Hand joint involvement	Wrist, MCP, or PIP joints among the symptomatic joints observed	1.5	0.4	33	12
Symmetric arthritis	Right and left joints involved for one or more of following: wrist, PIP, MCP, elbow, knee, ankle, MTP†	1.2	0.6	29	17
Rheumatoid nodules	Subcutaneous nodules in regions surrounding joints, extensor surfaces, or bony prominences	3.0	0.98	50	25
Serum rheumatoid factor positive	Positive result using any laboratory test that has a positive predictive value of 95 percent or more (i.e., is positive in no more than 5 percent of patients without rheumatoid arthritis)	8.4	0.4	74	13
Radiographic changes	Hand and wrist films show typical changes of erosions or loss of density adjacent to affected joints	11	0.8	79	21

*—Assumes overall probability of rheumatoid arthritis of 30 percent.

†—PIP, MCP, and MTP joints need not be absolutely symmetrical.

LR+ = positive likelihood ratio; LR- = negative likelihood ratio; PIP= proximal interphalangeal; MCP= metacarpophalangeal; MTP= metatarsophalangeal. Information from references 11 and 12.

erythematous. Some patients complain of “puffy” hands secondary to increased blood flow to inflamed areas. Prominent epitrochlear, axillary, and cervical lymph nodes may be noted. Muscles near inflamed joints often atrophy. Weakness is commonly out of proportion to pain on examination. Morning stiffness lasting at least 45 minutes after initiating movement is common. Patients often hold joints in flexion to minimize painful distension of joint capsules. Low-grade fever, fatigue, malaise, and other systemic complaints may arise, especially in an acute presentation.^{5,10}

DIAGNOSTIC CRITERIA

In clinical trials, rheumatoid arthritis is diagnosed formally using seven American Rheumatism Association (ARA) criteria (Table 1).^{11,12} In typical outpatient practice, a definitive diagnosis using these criteria may be difficult to obtain early in the disease process. During the initial visit, patients should be asked about degree of pain, duration of stiffness and fatigue, and functional limitations. A careful joint examination looking for the characteristics described above is vital.

DIFFERENTIAL DIAGNOSIS

Rheumatoid arthritis must be differentiated from a number of other disorders. Infection-related reactive

arthropathies, seronegative spondyloarthropathies, and other connective tissue diseases such as systemic lupus erythematosus may have symptoms in common with rheumatoid arthritis, as may an array of endocrine and other disorders (Table 2).^{5,10} Gout rarely coexists with rheumatoid arthritis, and a joint aspiration should be considered if gout is suspected.

DIAGNOSTIC TESTS

No single diagnostic test definitively confirms the diagnosis of rheumatoid arthritis. However, several tests can provide objective data that increase diagnostic certainty and allow disease progression to be followed. The American College of Rheumatology Subcommittee on Rheumatoid Arthritis (ACRSRA) recommends that baseline laboratory evaluations include a complete blood cell count with differential, rheumatoid factor, and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline evaluation of renal and hepatic function also is recommended because these findings will guide medication choices.² Table 3^{2,5,13} summarizes the test findings associated with rheumatoid arthritis.

Treatment

Joint destruction in rheumatoid arthritis begins within a few weeks of symptom onset; early treatment decreases

TABLE 2
Differential Diagnosis of Rheumatoid Arthritis

<i>Diagnosis</i>	<i>Comments</i>
Connective tissue diseases	Such as scleroderma and lupus
Fibromyalgia	Evaluate for trigger points.
Hemochromatosis	Iron studies and skin coloration changes may guide diagnosis.
Infectious endocarditis	Rule out murmurs, high fever, and history of intravenous drug use.
Polyarticular gout	Joints often erythematous; podagra commonly found; gout and rheumatoid arthritis rarely coexist, but calcium pyrophosphate deposition disease can accompany rheumatoid arthritis.
Polymyalgia rheumatica	Rheumatoid arthritis, unlike polymyalgia rheumatica, rarely presents with pain in the proximal joints of the extremities only.
Sarcoidosis	Granulomas likely, as are hypercalcemia and chest film findings.
Seronegative spondyloarthropathies, reactive arthritis	Tend to be more asymmetric than rheumatoid arthritis. More commonly involve the joints of the spine. Evaluate for history of psoriasis, Reiter's comorbidities, inflammatory bowel disease. Reactive arthritis can be postinfective, sexually acquired, or related to gastrointestinal disorders.
Still's disease	Tends to present with fever, leukocytosis with left shift, sore throat, splenomegaly, liver dysfunction, and/or rash.
Thyroid disease	Consider thyroid-stimulating hormone level depending on symptoms.
Viral arthritis	Consider parvovirus, hepatitis B.

Information from references 5 and 10.

the rate of disease progression.¹⁴ Therefore, it is imperative to diagnose the disease and initiate treatment as soon as possible. The ACRSRA recommends that patients with suspected rheumatoid arthritis be referred within three months of presentation for confirmation of diagnosis and initiation of treatment with disease-modifying antirheumatic drugs (DMARDs).² Therapeutic goals include preservation of function and quality of life, minimization of pain and inflammation, joint protection, and control of systemic complica-

tions.^{2,5} *Figure 1*^{2,4} outlines an approach to the treatment of a patient with rheumatoid arthritis.

PHARMACOTHERAPY

Pharmacotherapy for rheumatoid arthritis generally involves a nonsteroidal anti-inflammatory drug (NSAID) for control of pain, with selective use of low-dose oral or intra-articular glucocorticoids, and initiation of a DMARD. Other analgesics also may be used, but details are outside the scope of this article. In past decades, pharmacologic treatment of rheumatoid arthritis was managed using a pyramid approach: symptom-alleviating treatment was started at diagnosis, and only with progression of symptoms were dosages changed or additional medications added. However, a "reverse pyramid" approach now is favored, in which DMARDs are initiated quickly to slow disease progression as early as possible (*Figure 1*^{2,4}).¹⁵ This change of approach is a result of several research findings: (1) joint damage begins early in the disease¹⁴; (2) DMARDs have significant benefits when used early; (3) the benefits of DMARDs may be enhanced when the drugs are used in combination¹⁶⁻¹⁸; (4) a number of new DMARDs are available, with good evidence of beneficial effect.¹⁹

Patients with mild disease and normal radiographic findings can begin treatment with hydroxychloroquine (Plaquenil), sulfasalazine (Azulfidine), or minocycline (Minocin), although methotrexate also is an option. Patients with more severe disease or radiographic changes should begin treatment with methotrexate. If symptoms are not adequately controlled, leflunomide (Arava),

The Authors

J. ADAM RINDFLEISCH, M.D., M.PHIL., is clinical instructor and academic fellow in the Department of Family Medicine at the University of Wisconsin–Madison in Madison, Wis., where he also is an integrative medicine consultant. He received his medical degree from Johns Hopkins University School of Medicine, Baltimore, and completed a family practice residency with the University of Wisconsin–Madison. Dr. Rindfleisch obtained his master's degree in comparative social research at the University of Oxford, England.

DANIEL MULLER, M.D., PH.D., is associate professor in the Departments of Medicine (Rheumatology) and Medical Microbiology/Immunology at the University of Wisconsin–Madison. He obtained his medical microbiology degree at the University of Wisconsin–Madison and his medical degree at the State University of New York at Stony Brook. Dr. Muller completed a residency in internal medicine and a fellowship in rheumatology at the University of North Carolina at Chapel Hill.

Address correspondence to J. Adam Rindfleisch, M.D., M.Phil., 777 S. Mills St., Madison, WI 53715. Reprints are not available from the authors.

TABLE 3

Laboratory and Imaging Findings Associated with Rheumatoid Arthritis

<i>Laboratory test</i>	<i>Associated findings</i>
C-reactive protein*	Typically increased to >0.7 picograms per mL; may be used to monitor disease course.
Erythrocyte sedimentation rate*	Often increased to >30 mm per hour; may be used to monitor disease course.
Hemoglobin/hematocrit*	Slightly decreased; hemoglobin averages around 10 g per dL (100 g per L); normochromic anemia, also may be normocytic or microcytic.
Liver function*	Normal or slightly elevated alkaline phosphatase
Platelets*	Usually increased
Radiographic findings of involved joints*	May be normal or show osteopenia or erosions near joint spaces in early disease; wrist and ankle films are useful as baselines for comparison with future studies.
Rheumatoid factor*	Negative in 30 percent of patients early in illness; if initially negative, can repeat six to 12 months after disease onset; can be positive in numerous other processes (e.g., lupus; scleroderma; Sjögren's syndrome; neoplastic disease; sarcoidosis; various viral, parasitic, or bacterial infections); not an accurate measure of disease progression.
White blood count*	May be increased
Anticyclic citrullinated peptide antibody	Tends to correlate well with disease progression; increases sensitivity when used in combination with rheumatoid factor; more specific than rheumatoid factor (90 versus 80 percent); not readily available in many laboratories.
Antinuclear antibody	Limited value as a screening study for rheumatoid arthritis
Complement levels	Normal or elevated
Immunoglobulins	Elevated alpha-1 and alpha-2 globulins possible.
Joint fluid evaluation	Consider if an affected joint can be tapped and diagnosis is uncertain; straw-colored fluid with fibrin flecks often seen; fluid may clot at room temperature; 5,000 to 25,000 white blood cells per mm ³ (5 to 25 × 10 ⁹ per L) with 85 percent polymorphonuclear leukocytes a common finding; in rheumatoid arthritis, cultures are negative, there are no crystals, and fluid glucose level typically is low.
Urinalysis	Microscopic hematuria or proteinuria may be present in many connective tissue diseases.

*—Recommended for initial evaluation for rheumatoid arthritis.

NOTE: Renal function, although not as likely to change as a direct effect of disease, should be followed to assess renal effects of drug therapy. Information from references 2, 5, and 13.

azathioprine (Imuran), or combination therapy (methotrexate plus one of the newer agents) may be considered. Individual drug categories are discussed below.


NSAIDs. NSAIDs, salicylates, or cyclooxygenase-2 inhibitors are used for initial treatment of rheumatoid arthritis to reduce joint pain and swelling. However, because they do not alter the disease course, they should not be used alone.² Patients with rheumatoid arthritis are almost two times more likely to have serious complications from NSAID use than patients with osteoarthritis, and they should be observed closely for symptoms of gastrointestinal side effects.^{2,13} Cyclooxygenase-2 inhibitors must be used with caution, given recent findings regarding potential adverse effects.

Glucocorticoids. Steroids at dosages equivalent to less than 10 mg of prednisone daily are highly effective for relieving symptoms of rheumatoid arthritis² and can slow joint damage.²⁰ Steroid dosages should be kept at a minimum because of the high risk of side effects, which include osteoporosis, cataracts, cushingoid symptoms,

and abnormalities in blood glucose levels. The American College of Rheumatology (ACR) guidelines² recommend that patients being treated with glucocorticoids take 1,500 mg of calcium and 400 to 800 IU of vitamin D daily. When a single inflamed joint contributes to significant disability, injection of glucocorticoids is a safe and effective intervention; however, the effects are temporary. Infectious arthritis should be ruled out before injections are performed.² Symptoms may recur with steroid discontinuation, especially when high dosages were used, and most rheumatologists withdraw steroids slowly, over a month or more, to avoid rebound effects.²¹ Systemic steroids often are used as “bridging therapy” during the period when DMARDs have been initiated but have not yet taken effect, but some of the newer DMARDs have a relatively rapid onset of action.²

DMARDs. DMARDs should be considered for all patients with rheumatoid arthritis. Compliance, disease severity, physician experience, and the presence of various comorbidities guide medication choice. The

Treatment Approach for a Patient with Rheumatoid Arthritis



*—The following laboratory tests should be performed before methotrexate therapy begins, every two weeks for six weeks, then, if normal, every two months: complete blood count with differential, platelets, aspartate transaminase levels, albumin levels, and creatinine levels. When starting methotrexate, add 1 mg oral folic acid per day to decrease side effects, and caution the patient to avoid alcohol.

†—When adding another DMARD to methotrexate, decrease the dosage of methotrexate to 10 to 15 mg once per week.

Figure 1. Algorithm for treatment of a patient with rheumatoid arthritis. (DMARD = disease-modifying antirheumatic drug; SC = subcutaneous; IM = intramuscular.)

Information from references 2 and 4.

most commonly used medications are methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, infliximab (Remicade), and etanercept (Enbrel).² Sulfasalazine or hydroxychloroquine often are started first, but in more severe cases, methotrexate or combination

therapy may be first-line treatment. Increasing evidence indicates that combinations of DMARDs can be more effective than single-drug regimens. Women of child-bearing age should use adequate contraception when taking certain DMARDs because they could be harmful

to a fetus.¹⁹ *Table 4*^{2,13,19} lists DMARD dosing regimens, costs, times to onset of benefit, and adverse effects.

Newer DMARDs. Several new drugs with novel mechanisms of action have emerged in recent years, including leflunomide, tumor necrosis factor (TNF) antagonists, and anakinra (Kineret).¹⁹ Leflunomide is a competitive inhibitor of an intracellular enzyme needed for de novo pyrimidine synthesis by activated lymphocytes.¹⁹ Leflunomide slows progression of joint damage as measured radiographically, and it was found to prevent new joint erosions in 80 percent of patients over a two-year period.²²

TNF antagonists lower the levels of TNF- α , which is present in increased concentrations in the synovial fluid in patients with rheumatoid arthritis. Etanercept is a soluble TNF-receptor fusion protein. Its long-term effects are comparable with methotrexate in some studies,^{13,23} but it elicits improvement in symptoms much more rapidly, often within two weeks.²³ Infliximab, another TNF antagonist, is a chimeric IgG1 anti-TNF- α antibody. Patients who had a poor response to methotrexate had a greater response with infliximab than placebo (52 versus 17 percent, number needed to treat = 3).¹⁷ Adalimumab (Humira) also is a recombinant human IgG1 antibody and has an additive effect when taken with methotrexate.¹⁸ TNF antagonists are associated with an increased risk of infection, especially tuberculosis reactivation.¹⁹

Anakinra is a recombinant interleukin-1 receptor antagonist. Several randomized controlled trials^{19,24} have found it to be more effective than placebo when administered alone or in combination with methotrexate. Adverse effects include skin irritation at the site of injection, increased risk of infection, and leukopenia.¹⁹

Other new DMARDs are in development. Rituximab (Rituxan), an antibody to a surface receptor on B cells, has shown promise in preliminary studies. Anti-interleukin-6 receptor antibodies also are being evaluated.²⁵

ADJUNCTIVE THERAPIES

A number of additional, nonpharmacologic treatments for rheumatoid arthritis have been tried. Therapeutic fasting, dietary supplementation of essential fatty acids, and journaling have shown benefit,²⁶ as have spa therapies²⁷ and exercise.²⁸ Patient education²⁹ and a multidisciplinary approach to patient care³⁰ provide at least short-term benefits. Evidence is inconclusive regarding herbal medications,³¹ acupuncture,²⁶ and splinting.³² Surgery should be considered when pain is unacceptable, loss of motion is significant, or functional impairment is severe.² More information about nonmedical therapies is available in the online version of this article (<http://www.aafp.org/afp/20050915/1037.html>).

DURATION OF TREATMENT

Rheumatoid arthritis is a lifelong illness. Combinations of methotrexate and the new biologic agents can lead to remission in 30 to 40 percent of patients with rheumatoid arthritis, but for most patients, significant disease persists despite treatment.^{16,19} Complete remission rarely occurs. In clinical trials, improvement has been tracked using the ACR improvement criteria, most often ACR 20, ACR 50, or ACR 70. The numbers represent the percentage of improvement in the following criteria: number of tender joints, number of swollen joints, global disease activity (as assessed by the patient or by an observer), pain level, physical disability score, and acute phase response (as measured by CRP or ESR).³³ For the individual patient, health assessment questionnaires may be a more useful means of evaluating disease progression. Examples include the European League Against Rheumatism response criteria for rheumatoid arthritis and various daily activity score surveys.^{2,13} Radiologic assessment scales also are useful.^{2,34} Treatment should be guided by individual clinical response to various interventions. Changes in hemoglobin, ESR, and CRP may serve as helpful indicators of response to treatment, but platelet count and rheumatoid factor levels tend not to correlate well.¹³

COMPLICATIONS

Physicians should monitor patients with rheumatoid arthritis for potential complications, which are numerous. *Table 5*⁵ lists the most common of these.

Prognosis

Predictors of poor outcomes in the early stages of rheumatoid arthritis include a relatively low functional score early in the disease progression, lower socioeconomic status, lower education level, strong family history of the disease, and early involvement of many joints. Prognosis is worse in patients who have a high ESR or CRP level at disease onset, positive rheumatoid factor, or early radiologic changes.¹⁵ Thirty percent of patients with rheumatoid arthritis, usually those with the most severe forms of the disease, will not demonstrate an ACR 20 response (see Duration of Treatment section, above) to any treatment.¹³ However, patients with milder disease tend to benefit from early treatment. A study of patients with rheumatoid arthritis onset in the 1980s showed no increase in mortality with rheumatoid arthritis in the first eight to 13 years following diagnosis.³⁵ The standardized all-cause mortality ratio for patients with rheumatoid arthritis compared with the general population is 1.6,³⁶ but this may decrease with long-term use of new DMARDs.

Author disclosure: Nothing to disclose

TABLE 4
DMARDs for Treatment of Rheumatoid Arthritis

<i>DMARD</i>	<i>Dosage</i>	<i>Cost (generic)*</i>	<i>Time to benefit</i>	<i>Adverse effects</i>
Adalimumab (Humira)	40 mg SC every two weeks	\$1,316	A few days to four months‡	Infusion reactions; increased infection risk, including TB reactivation Rare: demyelinating disorders
Anakinra (Kineret)	100 to 150 mg SC per day	1,251	Within 12 weeks; lasting effects by 24 weeks	Infections and decreased neutrophil counts; headaches, dizziness; nausea Rare: hypersensitivity
Auranofin (Ridaura)	3 mg orally twice per day or 6 mg orally per day	215	Four to six months	Diarrhea Rare: leukopenia
Azathioprine (Imuran)	50 to 150 mg orally per day	76 (39 to 40)	Two to three months	Nausea Rare: leukopenia; sepsis; lymphoma
Cyclosporine (Gengraf, Neoral, generic)	2.5 to 5 mg per kg orally per day	288 to 231 (288 to 326)	Two to four months	Nausea; paresthesias, tremor; headaches; gingival hypertrophy; hypertrichosis Rare: hypertension; renal disease; sepsis
D-Penicillamine (Cuprimine)	250 to 750 mg orally per day	35 to 95	Three to six months	Nausea; loss of taste; rash; reversible platelet decrease Rare: proteinuria; late autoimmune disease
Etanercept (Enbrel)	25 mg SC twice per week or 50 mg SC per week	1,316	A few days to 12 weeks	Contraindicated in infection; mild injection site reactions Rare: demyelination
Hydroxychloroquine (Plaquenil)	200 to 400 mg orally per day	57 (33 to 37)	Two to six months	Nausea; headaches Rare: abdominal pain; myopathy; retinal toxicity
IM gold				
Gold sodium thiomalate (Myochrysin)	25 to 50 mg IM every two to four weeks	34	Six to eight weeks	Mouth ulcers; rash; vasomotor symptoms after injection Rare: leukopenia; thrombocytopenia; proteinuria; colitis
Aurothioglucose (Solganal)				
Infliximab (Remicade)	3 mg per kg IV at weeks zero, 2, and 6, then every eight weeks§	1,383 (for eight weeks)	A few days to four months‡	Infusion reactions; increased infection risk, including TB reactivation Rare: demyelinating disorders
Leflunomide (Arava)	100 mg orally per day for three days, then 10 to 20 mg orally per day	372	Four to 12 weeks (tending toward four)	Nausea, diarrhea; rash; alopecia; highly teratogenic, even after discontinuation Rare: leukopenia; hepatitis; thrombocytopenia
Methotrexate	12 to 25 mg orally, IM, or SC per week	Oral: 79 (57 to 65) IM or SC: (18 to 20)	One to two months	Nausea, diarrhea; fatigue; mouth ulcers; rash, alopecia; abnormal LFTs Rare: low WBC and platelets; pneumonitis; sepsis; liver disease; Epstein-Barr virus–related lymphoma; nodulosis
Minocycline (Minocin)	100 mg orally twice per day	231 (115 to 147)	One to three months	Dizziness; skin pigmentation
Staphylococcal protein A immunoadsorption (Prosorba column)	Extracorporeal; weekly for 12 weeks	20,433	Three months	Hypotension and anemia during procedure; catheter site infection, joint pain, fatigue
Sulfasalazine (Azulfidine)	2 to 3 g orally per day in divided doses	48 (14 to 31)	One to three months	Nausea, diarrhea; headache; mouth ulcers; rash, alopecia; contact lens staining; reversible oligospermia; abnormal LFTs Rare: leukopenia

DMARD = disease-modifying antirheumatic drug; SC = subcutaneous; TB = tuberculosis; CBC = complete blood count; ALT = alanine transaminase; TNF = tumor necrosis factor; LFT = liver function test; IM = intramuscular; IV = intravenous; AST = aspartate transaminase; WBC = white blood count.

Information from references 2, 13, and 19.

<i>Monitoring</i> [†]	<i>Comments</i>
Monitor for TB, histoplasmosis, and other infections; CBC and ALT at baseline and monthly until dose is stable; may continue every two to three months thereafter.	Monoclonal antibody to TNF- α ; shown to reduce disease activity with acceptable safety.
CBC at baseline, monthly for three months, then every three months	Interleukin-1 receptor antagonist; used when treatment with another DMARD has failed.
CBC and urine protein (by dipstick) every one to three months	Has modest effects compared with other DMARDs.
CBC every one to two weeks until dose is stable, then every one to three months	Has greater toxicity and is used less commonly than other DMARDs.
Creatinine every two weeks until dose is stable, then monthly; consider CBC, LFTs, and potassium level tests	Significant clinical benefit up to one year; adverse effects limit use.
CBC and urinary protein by dipstick every two weeks until dose is stable, then every one to three months	Used less commonly than other DMARDs.
CBC and ALT at baseline and monthly until dose is stable; may continue every two to three months thereafter.	Combination of TNF receptor and portion of IgG1; inhibits TNF- α ; slows joint damage.
Eye examinations every 12 months in patients older than 40 years and those with previous eye disease	Can be used when diagnosis uncertain; moderate effect but relatively low toxicity.
CBC and urinary protein by dipstick every two weeks until dose is stable, then with each injection	Has significant withdrawal rate in trials because of toxicity.
Monitor for TB, histoplasmosis, and other infections; CBC and ALT at baseline and monthly until dose is stable; may continue every two to three months thereafter.	Monoclonal antibody to TNF- α ; reduces disease activity with acceptable safety.
Hepatitis B and C serology in high-risk patients; CBC, creatinine, and LFTs monthly for six months, then every one to two months; repeat AST or ALT in two to four weeks if initially elevated, and adjust dose as needed.	Inhibits pyrimidine synthesis and may suppress T-cell activation; improves multiple clinical outcomes and delays radiographic changes; can be eliminated from system with cholestyramine in patients wishing to conceive.
CBC, creatinine, and LFTs monthly for six months, then every one to two months; repeat AST or ALT in two to four weeks if initially elevated, and adjust dose as needed; liver biopsy if no resolution on discontinuation.	Rapid onset (six to 10 weeks); tends to produce more sustained results over time than other DMARDs and lowers all-cause mortality; can be used when cause of polyarthritis uncertain; often combined with newer DMARDs.
None needed	Effective in combination with prednisone for management of new-onset rheumatoid arthritis.
Follow CBC	Used only in refractory patients when many other treatments have failed.
CBC every two to four weeks for three months, then every three months	Rapid onset (eight to 13 weeks); enteric, coated forms available; can be used when diagnosis uncertain; modest effects compared with other medications.

*—Average wholesale cost for one month's supply (unless otherwise indicated), based on Red Book, Montvale, N.J.: Medical Economics Data, 2004.

[†]—Monitoring guidelines are based on consensus guidelines and expert recommendations^{2,19} but may vary among physicians for some medications.

[‡]—When combined with methotrexate.

[§]—May be increased if incomplete response.

TABLE 5
Complications of Untreated Rheumatoid Arthritis

<i>Complication</i>	<i>Comments</i>
Anemia	Correlates with erythrocyte sedimentation rate and disease activity; three fourths of patients have anemia of chronic disease; one fourth of patients respond to iron therapy.
Cancer	May be secondary to treatments; lymphomas and leukemias two to three times more common in patients with rheumatoid arthritis; increased risk for various solid tumors; genitourinary cancer risk is reduced in rheumatoid arthritis, perhaps because of nonsteroidal anti-inflammatory drugs.
Cardiac complications	Pericarditis—one third of patients may have asymptomatic pericardial effusion at diagnosis; atrioventricular block—rare; myocarditis—diffuse inflammation can occur, may or may not be symptomatic.
Cervical spine disease	Tenosynovitis of transverse ligament can lead to instability of atlas on axis. Caution must be used during endotracheal intubation; may see loss of lordosis of the neck and decreased range of motion; C4-C5 and C5-C6 sUBLuxations are possible; may see joint space narrowing on lateral cervical spine films; avoid flexion films until odontoid fracture ruled out if injury is suspected; myelopathy can occur, with gradual onset of upper extremity weakness and paresthesias.
Eye problems	Episcleritis rarely occurs.
Fistula formation	Cutaneous sinuses form near affected joints, connecting bursa to the skin.
Increased infections	More likely to be an effect of rheumatoid arthritis treatment.
Hand joint deformities	Ulnar deviation at metacarpophalangeal joints; boutonniere deformity—flexed PIP and hyperextended DIP; swan neck deformity—the reverse of boutonniere, with flexed DIP and hyperextended PIP; thumb hyperextension; increased risk of tendon rupture
Other joint deformities	Frozen shoulder may develop; popliteal cysts can arise; carpal and tarsal tunnel syndromes common.
Respiratory complications	Lung nodules can coexist with cancers and form cavitory lesions; cricoarytenoid joint inflammation can arise, with hoarseness and laryngeal pain; pleuritis—present in 20 percent at onset of disease; not usually associated with pleuritic pain; interstitial fibrosis—rales may be noted on lung examination.
Rheumatoid nodules	Often have necrotic tissue in their centers; found in 20 to 35 percent of patients with rheumatoid arthritis; usually found on extensor surfaces of the limbs or other pressure points; may form nearly anywhere, including on the sclera, vocal cords, sacrum, or vertebral bodies.
Vasculitis	Forms include distal arteritis, pericarditis, peripheral neuropathy, cutaneous lesions, arteritis of viscera, and coronary arteritis; increased risk of developing if male sex, high rheumatoid factor titers, treatment with steroids, number of disease-modifying antirheumatic drugs prescribed; associated with increased risk of myocardial infarction.

PIP = proximal interphalangeal; DIP = distal interphalangeal.

Information from reference 5.

REFERENCES

- Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB, Kelley WN, eds. *Kelley's Textbook of rheumatology*. 7th ed. Philadelphia: W.B. Saunders, 2005:996-1042.
- American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. *Arthritis Rheum* 2002;46:328-46.
- Sokka T. Work disability in early rheumatoid arthritis. *Clin Exp Rheum* 2003;21(5 suppl 31):S71-4.
- Goldring SR. A 55-year-old woman with rheumatoid arthritis. *JAMA* 2000;283:524-31.
- Harris ED. Clinical features of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB, Kelley WN, eds. *Kelley's Textbook of rheumatology*. 7th ed. Philadelphia: WB Saunders, 2005:1043-78.
- Kuder SA, Peshimam AZ, Agraharam S. Environmental risk factors for rheumatoid arthritis. *Rev Environ Health* 2002;17:307-15.
- Mikuls TR, Cerhan JR, Criswell LA, Merlino L, Mudano AS, Burma M, et al. Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study. *Arthritis Rheum* 2002;46:83-91.
- Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. *Arthritis Rheum* 2004; 50:72-7.
- Tugwell P, Wells G, Peterson J, Welch V, Page J, Davison C, et al. Do silicone breast implants cause rheumatologic disorders? A systematic review for a court-appointed national science panel. *Arthritis Rheum* 2001;44:2477-84.
- Akil M, Amos RS. ABC of rheumatology. Rheumatoid arthritis—I: clinical features and diagnosis. *BMJ* 1995;310:587-90.

11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
12. Saraux A, Berthelot M, Chales G, Le Henaff C, Thorei JB, Hoang S, et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. *Arthritis Rheum* 2001;44:2485-91.
13. Scottish Intercollegiate Guidelines Network. Management of early rheumatoid arthritis. SIGN No. 48, December 2000. Accessed online July 19, 2005, at: <http://www.sign.ac.uk/guidelines/fulltext/48/index.html>.
14. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. *Ann Rheum Dis* 2002;61:290-7.
15. Boers M. Rheumatoid arthritis. Treatment of early disease. *Rheum Dis Clin North Am* 2001;27:405-14,x.
16. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. *Ann Intern Med* 1999;131:768-74.
17. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. *N Engl J Med* 2000;343:1594-602.
18. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial [published corrections appear in *Arthritis Rheum* 2003;48:855; *Arthritis Rheum* 2004;22:144]. *Arthritis Rheum* 2003;48:35-45.
19. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. *N Engl J Med* 2004;350:2167-79.
20. Kirwan JR; Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. *N Engl J Med* 1995;333:142-6.
21. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects. *Ann Intern Med* 2002;136:1-12.
22. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. *Arthritis Rheum* 2001;44:1984-92.
23. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published correction appears in *N Engl J Med* 2001;344:24,76]. *N Engl J Med* 2000;343:1586-93.
24. Nuki G, Breshnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2002;46:2838-46.
25. Moreland LW. Biologic therapies on the horizon for rheumatoid arthritis. *J Clin Rheumatol* 2004;10(suppl):S32-9.
26. Raket D, Muller D. Integrative approach to rheumatology. In: Kligler B, Lee RA, eds. *Integrative medicine: principles for practice*. New York: McGraw-Hill, 2004:667-95.
27. Verhagen AP, Bierma-Zeinstra SM, Cardoso JR, de Bie RA, Boers M, de Vet HC. Balneotherapy for rheumatoid arthritis. *Cochrane Database Syst Rev* 2004;(1):CD000518.
28. Van Den Ende CH, Vliet Vlieland TP, Munneke M, Hazes JM. Dynamic exercise therapy for rheumatoid arthritis. *Cochrane Database Syst Rev* 1998;(4):CD000322.
29. Riemsma RP, Kirwan JR, Taal E, Rasker JJ. Patient education for adults with rheumatoid arthritis. *Cochrane Database Syst Rev* 2003;(2):CD003688.
30. Vliet Vlieland TP, Breedveld FC, Hazes JM. The two-year follow-up of a randomized comparison of inpatient multidisciplinary team care and routine outpatient care for active rheumatoid arthritis. *Br J Rheumatol* 1997;36:82-5.
31. Little C, Parsons T. Herbal therapy for treating rheumatoid arthritis. *Cochrane Database Syst Rev* 2000;(4):CD002948.
32. Egan M, Brosseau L, Farmer M, Ouimet MA, Rees S, Wells G, et al. Splints/orthoses in the treatment of rheumatoid arthritis. *Cochrane Database Syst Rev* 2001;(4):CD004018.
33. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. *Arthritis Rheum* 1992;35:498-502.
34. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. *Arthritis Rheum* 1996;39:34-40.
35. Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. *Ann Rheum Dis* 1999;58:11-4.
36. Chehata JC, Hassell AB, Clarke SA, Matthey DL, Jones MA, Jones PW, et al. Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. *Rheumatology* 2001;40:447-52.